what would you tell week-1 you about ACHIEVE
what would you tell week-1 you about ACHIEVE. I would rather ask a basic question now than get this wrong quietly for two months. Because it is not a peptide, it is not subject to the same degradation pathways, does not require the absorption enhancers used for oral peptides, and can be formulated as a conventional…
oral semaglutide is a peptide with an absorption enhancer, this is not that
Standing reminder: unapproved compound, research material is not for human use, and no schedules for other members.
Small fix — the two programme names got swapped upthread and it changes which population the figure came from.
do not assume reconstitution intuitions apply, there is nothing to reconstitute
daily dosing, not weekly, so the exposure profile is different
the manufacturing story is genuinely different from the injectables
oral semaglutide is a peptide with an absorption enhancer, this is not that
Disagreeing with this bit: daily dosing is a different adherence problem, not a better one.
Disagreeing with this bit: daily dosing is a different adherence problem, not a better one.
Agreed, and it is why the oral peptide comparison keeps misleading people.
Analytically this is a small-molecule identity and purity problem, not a peptide one. The methods, the impurity classes and the reference standards are all different.
That is a phase 2 result being quoted as though the programme had reported.